Medscape InDiscussion: Renal Cell Carcinoma

Author: Medscape

Listen to Medscape InDiscussion: Renal Cell Carcinoma, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984237). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Medicine, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

S2 Episode 6: What's New in the Field of Neoadjuvant Therapy and Renal Cell Carcinoma?
Episode 6
Thursday, 7 September, 2023

Drs Sumanta Pal and Jose A. Karam, MD, discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, immuno-oncology, and the need for more studies to explore the role of neoadjuvant therapy in RCC. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984249). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges Into Opportunities https://pubmed.ncbi.nlm.nih.gov/35248412/ Axitinib https://reference.medscape.com/drug/inlyta-axitinib-999715#10 Phase 2 Trial of Neoadjuvant Axitinib in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/24560330/ Renal Clear Cell Cancer https://www.ncbi.nlm.nih.gov/books/NBK563230/ Response Evaluation Criteria in Solid Tumors https://radiopaedia.org/articles/response-evaluation-criteria-in-solid-tumours?lang=us Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/ Tyrosine Kinase Inhibitors and Immunotherapy Combinations in Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/32215057/ A Phase II Study of Pazopanib in Patients With Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma https://pubmed.ncbi.nlm.nih.gov/25813447/ Bevacizumab (Rx) https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257 Everolimus (Rx) https://reference.medscape.com/drug/afinitor-zortress-everolimus-999101 Nivolumab (Rx) https://reference.medscape.com/drug/opdivo-nivolumab-999989 A Pilot Randomized Study Evaluating Nivolumab (Nivo) Or Nivo + Bevacizumab (Bev) Or Nivo + Ipilimumab (Ipi) in Patients With Metastatic Renal Cell Carcinoma (MRCC) Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy (Bx) https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4501 Ipilimumab (Rx) https://reference.medscape.com/drug/yervoy-ipilimumab-999636#10 TNM Classification https://www.ncbi.nlm.nih.gov/books/NBK553187/ A Phase II, Single-Arm Trial of Neoadjuvant Axitinib Plus Avelumab in Patients With Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy (NEOAVAX) https://pubmed.ncbi.nlm.nih.gov/31023100/ Inferior Venal Caval Thrombus https://emedicine.medscape.com/article/1933035-overview A Phase II Study of Neoadjuvant Axitinib for Reducing the Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion (NAXIVA) https://pubmed.ncbi.nlm.nih.gov/35739300/ Surgical Management of Renal Cell Carcinoma With Associated Tumor Thrombus Extending Into the Inferior Vena Cava: A 10-Year Single-Center Experience https://pubmed.ncbi.nlm.nih.gov/30817278/